REG - Malin Corp PLC - Directorate Change

MalinAnnouncement

25/03/2020 08:05

RNS Number : 4800H
  
Malin Corporation PLC
  
25 March 2020
  
 

Malin Corporation plc
 
Directorate Change
Appointment of New Directors 
 
Dublin-Ireland, 25 March 2020: Malin Corporation plc. (Euronext Growth Dublin:MLC) ("Malin", the "Company"), a company investing in highly innovative life sciences companies, today announces the appointment of Dr Kirsten Drejer and Luke Corning as Non-Executive Directors and Darragh Lyons, Chief Executive Officer, as Executive Director, effective from 24 March 2020. 
 
Welcoming today's announcement, Chairman Liam Daniel said:
 
"On behalf of the Malin Board, I am delighted to welcome Dr Kirsten Drejer and Luke Corning as Non-Executive Directors, who bring highly relevant skills and experience to Malin. Recognising the importance of strong leadership at an executive level, we appointed Darragh Lyons to the role of CEO in September 2019, who also now joins the Board. I am confident that the new appointments will add quality and depth to Malin's healthcare focus and governance framework as we look forward to important and value enhancing milestones across our investee companies in 2020."
 
Dr Kirsten Drejer founded and served as CEO of Symphogen, a Danish private biopharmaceutical company, and has extensive board experience on both private and public companies across the life sciences sector, including Zealand Pharma, where she currently serves as vice-chairman of the board, Bioporto and Alligator Bioscience.
Luke Corning is head of the Credit and Special Situations group at Pentwater Capital Management LP ("Pentwater").  Pentwater holds a 26% economic interest in Malin through a number of counterparties, as announced in October 2019.   Over the course of his investment management career, Mr Corning has served on the boards of several private and public companies across a range of sectors.
Darragh Lyons was appointed CEO of Malin in September 2019 having previously held the positions of Chief Business and Financial Officer, and Chief Financial Officer of Malin. 
 
Regulatory disclosures 
 
Other than as set out in the Schedule hereto, there are no other matters required to be disclosed pursuant to Schedule Two, paragraph (g) of Chapter 5: Additional Rules for the Euronext Growth Market operated by Euronext Dublin as regards the appointments of Dr Kirsten Drejer or Messrs. Corning or Lyons.
 
ENDS
 
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com  
 
For further information, please contact:
 
Malin 
Jessica Bergin, Investor Relations & External Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
 
Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
 
Liberum (Joint Broker)
Bidhi Bhoma / Euan Brown
Tel: +44 (0) 20 3100 2000
 
Consilium Strategic Communications 
Mary-Jane Elliott / Chris Welsh / Angela Gray
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com 
 
Powerscourt (Irish media enquiries)          
Jack Hickey
Tel: +353 83 448 8339                            
malin@powerscourt-group.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schedule
 
Regulatory Disclosures
 
Dr Kirsten Aarup Drejer (née Philipsen) (Age 64)
 



Current Directorships


Directorships within the past 5 years




Alligator Bioscience AB


Symphogen A/S




Zealand Pharma A/S


Danish Growth Fund (Vaekstfonden)




Bioporto Diagnostics A/S


Bionor Pharma AS




Bioneer A/S








Lyhne Life








Antag Therapeutics ApS








ResoTher Pharma ApS







 
Luke David Corning (Age 38)
 



Current Directorships


Directorships within the past 5 years




JW Aluminum Inc.


American Apparel Inc.




American Standard Energy Corp.







 
Luke Corning is an employee of Pentwater Capital Management LP, an organisation which holds a 26% economic interest in Malin through a number of counterparties.
 
Luke Corning was appointed to the board of American Apparel, Inc. ("American Apparel") between 5 February 2016 and 31 March 2017. American Apparel voluntarily filed for Chapter 11 bankruptcy protection on November 14, 2016. On November 14, 2016, Gildan Activewear Inc. ("Gildan") entered into an asset purchase agreement with American Apparel that served as the initial bid in a Bankruptcy Court-supervised auction. Following approval by the Bankruptcy Court, on February 8, 2017, Gildan announced that it had completed the acquisition of the American Apparel brand and certain assets from American Apparel. 
 
Darragh Fergal Lyons (Age 39)
 



Current Directorships


Directorships within the past 5 years




Malin Life Sciences Holdings Limited


Malin Corporation plc




Malin Life Sciences International Limited


Harbour Square Corporate Secretaries Limited




An2H Discovery Limited


3D4 Medical Limited 




Altan Pharma Limited


Brandon Point Industries Unlimited Company




Nidus Laboratories Ireland Limited


Brandon Point Management Services Unlimited Company




Hatchill Limited


Malin Life Sciences (UK) Limited 




NeuVT Limited








Emba Medical Limited








Emba Neuro Limited








Neurobiometrix Limited








Serenus Biotherapeutics Limited








Brandon Point Enterprises 1 Limited








Malin Life Sciences (US) Inc.







 
Darragh Lyons holds 54,176 Ordinary Shares and 65,250 unvested Restricted Stock Units in Malin. He has a 1% economic interest in Brandon Point Industries, an Irish life sciences holding company, which holds 3,279,299 Founder A Ordinary Shares in Malin. The Founder A Ordinary Shares convert to Ordinary Shares upon the achievement by the Company of performance thresholds or upon a change of control.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
BOASEFEDLESSEDD